Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 4/20 | 0.56 |
| ▸ | HTR2C | P28335 | 4/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20995870 | 1.00 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL22049908 | 0.91 | NFE2L2 (0.83) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL12152585 | 0.90 | NFE2L2 (0.82) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL13790315 | 0.90 | NFE2L2 (0.96) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL21030098 | 0.88 | NFE2L2 (1.00) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL862515 | 0.82 | NFE2L2 (0.68) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL723352 | 0.81 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL1755404 | 0.81 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL723353 | 0.81 | NFE2L2 (0.78) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL11895621 | 0.81 | NFE2L2 (0.71) | NFE2L2PTGS1PTGS2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205127-A1 | COSMETIC AND NON-COSMETIC COMPOSITIONS AND METHODS OF USE | K&K BIOTECH (US) | 2025-06-26 | — | — | US | disclosed |
| US-12274773-B2 | Cosmetic compositions and methods of use | K&K BIOTECH (US) | 2025-04-15 | — | — | US | disclosed |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | TRUJILLO KRISTINA (US) | 2022-01-27 | — | — | US | disclosed |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | K&K BIOTECH (US) | 2020-12-24 | — | — | US | disclosed |
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | STC UNM (US) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190160021-A1 | Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2 | NFKBIA, NFE2L2, NFKB2 | NFE2L2 2/4885PTGS1 312/4885PTGS2 476/4885 |
| US-12274773-B2 | Cosmetic compositions and methods of use | KEAP1, NFE2L2, NQO1 | NFE2L2 2/4885PTGS1 127/4885PTGS2 128/4885 |
| US-20220023172-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | NFKBIA, IKBKB, NFKB2 | NFE2L2 9/4885PTGS1 263/4885PTGS2 254/4885 |
| US-20200397676-A1 | COSMETIC COMPOSITIONS AND METHODS OF USE | KEAP1, NFE2L2, NQO1 | NFE2L2 2/4885PTGS1 127/4885PTGS2 128/4885 |
| US-20250205127-A1 | COSMETIC AND NON-COSMETIC COMPOSITIONS AND METHODS OF USE | KEAP1, NFE2, NFE2L2 | NFE2L2 3/4885PTGS1 151/4885PTGS2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.